Natco Pharma Ltd. said on Friday it has added two injectible drugs for sale in the United States under an existing marketing tie-up with Akorn Inc, reports Reuters.

The drugs are used in the prevention of nausea and vomiting associated with chemotherapy.

With this, the total number of products sold under the tie-up had risen to four, including two other oncology products, the Indian company said in a statement.

Akorn also files abbreviated new drug applications for Natco's bulk drugs on a profit-sharing basis.